Provided by Tiger Trade Technology Pte. Ltd.

Lakefront Biotherapeutics

29.73
+0.22000.75%
Post-market: 29.730.00000.00%16:00 EDT
Volume:212.54K
Turnover:6.31M
Market Cap:1.96B
PE:2.88
High:29.95
Open:29.51
Low:29.33
Close:29.51
52wk High:36.24
52wk Low:25.68
Shares:65.90M
Float Shares:23.98M
Volume Ratio:0.52
T/O Rate:0.89%
Dividend:- -
Dividend Rate:- -
EPS(TTM):10.31
EPS(LYR):5.72
ROE:20.12%
ROA:9.93%
PB:0.54
PE(LYR):5.20

Loading ...

Lakefront Biotherapeutics' Gamgertamig Has Meaningful Opportunity in Rare Autoimmune Diseases, RBC Says

MT Newswires Live
·
Sep 23

RBC Upgrades Lakefront Biotherapeutics to Outperform From Sector Perform, Adds Speculative Risk, Raises Price Target to $45 From $26

MT Newswires Live
·
Sep 23

Lakefront Biotherapeutics Nv : RBC Raises to Outperform from Sector Perform; Raises Target Price to $45 from $26

THOMSON REUTERS
·
Sep 23

Analysts Conflicted on These Healthcare Names: Alnylam Pharma (ALNY), Lakefront Biotherapeutics (LKFT) and BioNTech SE (BNTX)

TIPRANKS
·
Aug 31

Lakefront Biotherapeutics Autoimmune Disorder Pemphigus Treatment Gets FDA Orphan Drug Designation

Dow Jones
·
Aug 25

Lakefront Biotherapeutics granted orphan drug designation for gamgertamig

TIPRANKS
·
Aug 25

Lakefront Biotherapeutics Nv : TD Cowen Reinstates Coverage with Buy Rating

THOMSON REUTERS
·
Aug 21

Lakefront Biotherapeutics is Maintained at Sector Perform by RBC Capital

Dow Jones
·
Aug 11

RBC Adjusts PT on Lakefront Biotherapeutics to $26 From $28, Keeps Sector Perform Rating

MT Newswires Live
·
Aug 11

Morgan Stanley Adjusts PT on Lakefront Biotherapeutics to $26 From $30, Maintains Equalweight Rating

MT Newswires Live
·
Aug 11

Lakefront Biotherapeutics NV Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 11

Lakefront Biotherapeutics Q2 EPS $0.29 Beats $(13.52) Estimate, Sales $21.624M Beat $7.210M Estimate

Benzinga Earnings
·
Aug 11

Lakefront Biotherapeutics NV Expected to Post a Loss of €4.64 a Share - Earnings Preview

Reuters
·
Aug 08

Earning Preview: Lakefront Biotherapeutics this quarter’s revenue is expected to decrease by 88.74%, and institutional views are constructive

Earnings Agent
·
Aug 03

Lakefront Biotherapeutics resumed with an Equal Weight at Morgan Stanley

TIPRANKS
·
Jul 10

Judah Frommer Maintains Hold on LKFT, Citing Early but Strategic Gamgertamig Acquisition and Limited Economic Upside

TIPRANKS
·
Jul 10

Lakefront Biotherapeutics Launches 50 Million Euros Share Repurchase Program

MT Newswires Live
·
Jun 10

Lakefront Biotherapeutics announces EUR 50M share repurchase program

TIPRANKS
·
Jun 10

Lakefront Biotherapeutics Names Eric Hedrick as Chief Medical Officer

MT Newswires Live
·
Jun 09

Dermatomyositis Trial Update Sets Context For LKFT’s Autoimmune Pipeline

TIPRANKS
·
May 15